Condition
Renal Disease, End-Stage
Total Trials
5
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 4 (2)
Trial Status
Completed3
Withdrawn1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03239808Not ApplicableActive Not RecruitingPrimary
Incremental Haemodialysis in Incident Patients
NCT01691196Withdrawn
Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
NCT01233882Phase 1CompletedPrimary
Bosutinib In Subjects With Renal Impairment
NCT00125775Phase 4Completed
Does Extra-High Dose Hepatitis B Vaccination Confer Longer Serological Protection in Peritoneal Dialysis Patients?
NCT00035178Phase 4Completed
Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis
Showing all 5 trials